-
Sale!
A comprehensive guide to risk-based validation approaches for pharmaceutical and medical device manufacturing, providing strategies to prioritize validation efforts based on product risk.Sale!
Analysis of pharmaceutical cGMP compliance risk and regulatory enforcement trends 2023-2025.Sale!
FDA regulatory trends and risk management strategies for clinical development of drugs and devices.Sale!
Comprehensive strategies for establishing robust GMP compliance programs including QMS, risk management, supplier quality, and advanced manufacturing approaches.Sale!
Quality by Design (QbD) is a paradigm shift that redefines quality assurance in pharmaceutical manufacturing by building quality into product and process design rather than relying solely on end-product testing.Sale!
Detailed strategies for equipment and software validation using risk-based approaches aligned with current FDA guidance and industry best practices.Sale!
Sale!
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart D (Equipment) with direct links to Form 483 observations and Warning Letters from 2017-2025.Sale!
Comprehensive records and reports enforcement data 2017-2025Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart D – Document Controls (§820.40). Form 483 observations and Warning Letters 2017–2025.Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart E – Purchasing Controls (§820.50). Form 483 observations and Warning Letters 2017–2025.
ComplyFDA delivers authoritative compliance intelligence for pharmaceuticals, medical devices, biologics, and combination products, giving your team the clarity needed to strengthen inspection readiness, evaluate compliance risks, and support continuous quality improvement.
services.
get in touch.
© 2012 - 2026 • Avada is a Website Builder for WordPress and eCommerce • All Rights Reserved • Developed by ThemeFusion
Go to Top
